

FAX Completed Form and Applicable Progress Notes to:

(410) 424-4037

USFHP Pharmacy Prior Authorization Form

| To be completed by Requesting provider | | | | |
|--|----------------------|--|--|--|
| Drug Name: | Strength: | | | |
| | | | | |
| Dosage/Frequency (SIG): | Duration of Therapy: | | | |
| | | | | |

Questions? Contact the Pharmacy Dept at: (888) 819-1043, option 4

Clinical Documentation must accompany form in order for a determination to be made.

Prior authorization does not expire.

| Step | Please complete patient and physician information (please print): | | | | | | | |
|------|---|---|---------------------------|------------------------------------|-----------------------|--|--|--|
| 1 | Patient | Name: | Physician Name: | /sician Name: Address: | | | | |
| | Addres | s: | Address: | | | | | |
| | 0 | | | | | | | |
| | Sponso Date of | | Phone #: Secure Fax #: | | | | | |
| Step | Date of Birth: Secure Fax #: Please complete the clinical assessment: | | | | | | | |
| 2 | | | | | | | | |
| 4 | 1. Is the patient 18 years of age or older? | | | Yes | 🗆 No | | | |
| | | | Proceed to | question 2 | STOP | | | |
| | | | | | Coverage not approved | | | |
| | 2. Is the requested medication prescribed by or in consultation with a nephrologist? | | | Yes | □ No | | | |
| | | Proceed to | question 3 | STOP | | | | |
| | | | | | Coverage not approved | | | |
| | Not | What is the indication or diagnosis? | Hyperphose | sphatemia in c | hronic kidney disease | | | |
| | | Note: Non-FDA approved uses are NOT approved, | (CKD) - Proce | (CKD) - Proceed to question 4 | | | | |
| | | including constipation-predominant irritable bowel syndrome (IBS-C). | | Other – STOP Coverage not approved | | | | |
| | 4. | Has the patient been receiving maintenance dialysis for at least 3 months? | | Yes | □ No | | | |
| | | | Proceed to | question 5 | STOP | | | |
| | | | | | Coverage not approved | | | |
| | 5. | Is the patient's serum phosphate level greater than 5.5. mg/dL and less than 10 mg/dL? | | Yes | □ No | | | |
| | | | Proceed to | question 6 | STOP | | | |
| | | | | | Coverage not approved | | | |
| | 6. | Has the patient tried and had an inadequate | | Yes | □ No | | | |
| | response to at least two phosphate binders (f example, sevelamer (Renagel, Renvela), | | Sign and c | late below | Proceed to question 7 | | | |
| | | lanthanum (Fosrenol), ferric citrate (Auryxia), sucroferric oxyhydroxide (Velphoro), calcium carbonate, calcium acetate)? | | | | | | |

TRICARE Prior Authorization Request Form for tenapanor (Xphozah)

| 7. Has the patient tried and been unable to tolerate at least two phosphate binders (for example, sevelamer (Renagel, Renvela), lanthanum (Fosrenol), ferric citrate (Auryxia), sucroferric oxyhydroxide (Velphoro), calcium carbonate, calcium acetate)? | ☐ Yes Sign and date below | ☐ No Proceed to question 8 |
|--|------------------------------|---------------------------------------|
| Does the patient have a contraindication to at least two phosphate binders (for example, sevelamer (Renagel, Renvela), lanthanum (Fosrenol), ferric citrate (Auryxia), sucroferric oxyhydroxide (Velphoro), calcium carbonate, calcium acetate). Contraindications to phosphate binders includes bowel obstruction, iron overload, or hypercalcemia? | ☐ Yes Sign and date below | ☐ No Proceed to question 9 |
| 9. Has the patient had intolerance to any dose of phosphate binder therapy? | ☐ Yes Sign and date below | ☐ No STOP Coverage not approved |

| Step | I certify the above is true to the best of my knowledge. Please sign and date: |
|------|--|
| 3 | |

Prescriber Signature

-

Date

[8 May 2024]

| For Internal Use Only | | | | |
|-----------------------|-------------------------------|--|--|--|
| Approved: | Duration of Approval:month(s) | | | |
| Denied: | Authorized By: | | | |
| Incomplete/Other: | PA#: | | | |
| Date Faxed to MD: | Date Decision Rendered: | | | |